Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: liraglutide
DRUG: sitagliptin
DRUG: placebo
DRUG: placebo

Sponsor

Novo Nordisk A/S